Physician profile
Maureen Whelihan
NPI 1104913102
$52,969.50
in general payments reported to CMS, 2019-2025
30 companies · $12K in 2025
The $12K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,649 · 2020: $371 · 2021: $1,251 · 2022: $11K · 2023: $12K · 2024: $14K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Honoraria: $11K · Food and Beverage: $1,000 · Education: $99.99 · Travel and Lodging: $99.78 · Gift: $7.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,840.00 |
| Honoraria | $10,750.00 |
| Food and Beverage | $1,000.21 |
| Education | $99.99 |
| Travel and Lodging | $99.78 |
| Gift | $7.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $27,923.57 | 2022-2025 | |
| Dysis Medical, INC. | $9,632.29 | 2021-2022 | |
| Astellas Pharma US INC | $8,749.95 | 2022-2025 | Veozah |
| Therapeuticsmd, INC. | $2,447.74 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,829.23 | 2025 | |
| Scynexis, INC. | $383.39 | 2022 | |
| Abbvie INC. | $309.39 | 2019-2024 | Lo Loestrin Fe, Orilissa |
| Myovant Sciences INC. | $289.62 | 2021-2022 | |
| Amgen INC. | $232.88 | 2021-2022 | |
| Novo Nordisk INC | $129.01 | 2023-2024 | Wegovy |
| Merz North America, INC. | $124.37 | 2020 | |
| Exeltis, USA INC. | $124.02 | 2020-2025 | Slynd |
| Mayne Pharma Commercial LLC | $117.30 | 2021-2025 | |
| Evofem Biosciences, INC. | $93.09 | 2020-2021 | |
| Millicent US INC | $79.61 | 2019-2024 | Femring, Intrarosa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $74.71 | 2021-2025 | Thinprep 2000 Processor, Aptima |
| Allergan, INC. | $70.56 | 2019-2020 | |
| Eisai INC. | $69.32 | 2020-2021 | |
| Antares Pharma, INC. | $50.00 | 2022 | |
| Sumitomo Pharma America, INC. | $39.16 | 2023-2024 | Myfembree |
| Merck Sharp & Dohme LLC | $38.72 | 2019 | |
| Mylan Pharmaceuticals INC. | $29.95 | 2022 | |
| Virtus Pharmaceuticals LLC | $28.13 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $25.10 | 2022 | |
| Agile Therapeutics, INC. | $18.51 | 2021 | |
| Organon LLC | $15.33 | 2025 | Nexplanon |
| Avion Pharmaceuticals | $15.17 | 2021 | |
| Pfizer INC. | $14.74 | 2022 | |
| Currax Pharmaceuticals LLC | $14.64 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Whelihan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.